Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valinomycin is a naturally occurring cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related Streptomyces species[1][4][6]. It consists of three units each of L-valine, D-valine, D-alpha-hydroxyisovaleric acid, and L-lactic acid linked alternately to form a 36-membered macrocyclic ring[1][6]. Valinomycin acts as a highly selective potassium ion transporter across lipid membranes, facilitating the movement of K⁺ ions down their electrochemical gradient while excluding sodium ions due to its structural selectivity[4][7]. This disrupts cellular ionic balance and can induce cell death through membrane depolarization. Its primary use is as a biochemical tool in research; it has also demonstrated potent antiviral activity in vitro (e.g., against SARS-CoV)[3], but its high toxicity limits therapeutic application. Valinomycin is extremely toxic to mammals as well as bacteria due to its non-selective disruption of cellular ionic gradients[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valinomycin.